PeptideClinicLocatortitle: Adipotide (FTPP) lastReviewed: "2026-02" faqs:
- question: Is Adipotide (FTPP) FDA-approved for weight loss? answer: No, Adipotide is not FDA-approved and is available for research purposes only.
- question: How does Adipotide work in the body? answer: Adipotide targets prohibitin receptors on adipose tissue vasculature, causing apoptosis in vascular endothelial cells.
- question: What are the potential side effects of Adipotide? answer: Side effects are not well-documented in humans, as it is primarily studied in preclinical settings.
- question: Can I get Adipotide through my insurance? answer: Adipotide is not covered by insurance as it is not approved for clinical use.
- question: Are there any related peptides to Adipotide? answer: Yes, related peptides include Tesamorelin and AOD9604.
## Overview
Adipotide, also known as FTPP, is a synthetic peptide developed as a targeted proapoptotic compound. It has garnered interest primarily for its potential application in weight-loss therapies by specifically targeting and reducing adipose tissue. However, it is crucial to note that Adipotide is not approved by the FDA for any medical use and is available strictly for research purposes.
Researchers are intrigued by Adipotide due to its unique mechanism of action, which involves inducing apoptosis in the blood vessels that supply adipose tissue. Despite promising preclinical results, Adipotide remains in the research phase, and its safety and efficacy in humans are not yet established. Therefore, any clinical application of Adipotide outside of controlled studies is not supported by regulatory authorities.
## How It Works (Mechanism of Action)
Adipotide operates by binding to prohibitin receptors located on the vasculature of adipose tissues. This binding disrupts mitochondrial membranes within the vascular endothelial cells, leading to apoptosis, or programmed cell death, of these cells. This process effectively reduces the blood supply to adipose tissue, potentially leading to a decrease in fat mass. The specific mechanism has been studied primarily in animal models, and its applicability to human physiology is still under investigation.
## Primary Uses
### Angiogenesis Inhibition
Adipotide has been explored for its ability to inhibit angiogenesis, the formation of new blood vessels, which is a critical process in the maintenance of adipose tissue. The evidence for this use is primarily from animal studies, showing potential in reducing fat deposits through vascular targeting.
### Vascular Remodeling
The peptide's mechanism suggests it could play a role in vascular remodeling, specifically in adipose tissue. This potential use is still in the preclinical research phase, with studies focusing on its effects on vascular structures in animal models.
### Adipose Tissue Metabolism
Adipotide's impact on adipose tissue metabolism is of significant interest for weight-loss research. By inducing apoptosis in the blood vessels of fat tissue, it may alter the metabolic activity within these tissues. However, this application is not supported by human clinical trials and remains theoretical based on preclinical data.
## FDA & Regulatory Status
Adipotide is not approved by the FDA for any therapeutic use. It is classified as a research-only compound, meaning it can be used in laboratory settings for scientific studies but not in clinical practice. There are no FDA enforcement actions against Adipotide, but its use is restricted to non-clinical research environments.
## Clinical Evidence
The evidence supporting Adipotide's effects comes predominantly from preclinical studies. Notably, animal models have demonstrated its potential in reducing fat tissue through targeted apoptosis. However, there are no registered human clinical trials (NCT numbers) available, and the transition from animal models to human applications remains speculative. Further research is required to establish its safety and efficacy in humans.
## Side Effects & Safety
The side effects of Adipotide are not well-documented in human subjects due to the lack of clinical trials. In preclinical studies, potential side effects observed in animal models include changes in kidney function and blood chemistry. The absence of human data necessitates caution, and any potential use in humans should be approached within controlled research settings.
## What to Expect at a Clinic
As Adipotide is not approved for clinical use, it is not typically available at clinics for patient treatment. Researchers interested in studying Adipotide may engage in structured research protocols where the peptide is administered under controlled conditions. These studies would involve detailed informed consent processes and rigorous monitoring of participants.
## Cost & Insurance
Adipotide is not legally available for purchase as a therapeutic agent, and thus, it is not covered by insurance. Costs associated with Adipotide would typically be related to research expenses rather than patient treatment. Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA) do not apply to non-approved research compounds.
## Related Peptides
- [Tesamorelin](/peptides/tesamorelin) is another peptide explored for its effects on adipose tissue, particularly in HIV-associated lipodystrophy.
- [AOD9604](/peptides/aod9604) is related in its potential application for weight management and is under investigation for similar metabolic effects.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.
